A Phase 3 Study of MK-4280A (Coformulated Favezelimab [MK-4280] Plus Pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PD-L1 Positive Colorectal Cancer

• Metastatic, unresectable colorectal adenocarcinoma, PDL1+
• Has measurable disease per RECIST 1.1 
• Has been previously treated for the disease and radiographically progressed on or after or could not tolerate standard treatment.
• Submits an archival (≤ 5 years) or newly obtained tumor tissue sample or newly obtained tumor tissue sample that has not been previously irradiated.
• ECOG 0-1
• Life Expectancy >= 3 months
• Ability to swallow oral medications
• Has adequate organ function.
• MMR proficient
• Does not have active central nervous system (CNS) metastases and/or carcinomatous meningitis or leptomeningeal disease.
• Has not received prior therapy with an anti-programmed cell death 1 (PD-1), anti-programmed death ligand 1 (PD-L1), or anti-programmed cell death ligand 2 (PD-L2), anti-lymphocyte activation gene 3 (LAG-3) antibody, with a tyrosine kinase inhibitor (TKI; eg, lenvatinib) other than rapidly accelerated fibrosarcoma (RAF) inhibitors (binimetinib is permitted if combined with a RAF inhibitor), or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein 4, OX-40, cluster of differentiation [CD] 137).
• Has not previously received regorafenib or TAS-102.
• Has not received prior radiotherapy within 2 weeks of start of study intervention.

Primary Objective: Overall Survival